Primary spermatic cord tumors: disease characteristics, prognostic factors, and treatment outcomes.
BACKGROUND
Experience with management of spermatic cord tumors (SCTs) is uncommon. We utilized a large population-based cancer registry to characterize the demographic, pathological, treatment characteristics, and outcomes of SCTs.


METHODS
The Surveillance, Epidemiology, and End Results database (1973-2007) was queried.


RESULTS
From the database, 362 patients were identified with SCT. The annual incidence of SCT was 0.3 cases per million and did not change over time. The most common histologic types were liposarcoma (46%), leiomyosarcoma (20%), histiocytoma (13%), and rhabdomyosarcoma (9%). The median age of diagnosis for rhabdomyosarcomas was (26.3 y), whereas for other SCTs, it was (64.7 y) (P<0.001). On multivariate analysis, a worse outcome was observed with undifferentiated tumor grade, distant disease, positive lymph nodes, and leiomyosarcoma or histiocytoma cell histology.


CONCLUSIONS
We describe the largest cohort of SCT studied to date. Liposarcoma was most common, while leiomyosarcoma and histiocytoma histologic subtypes were observed to be the most aggressive. Multivariate analysis revealed that tumor grade, stage, histologic type, and lymph node involvement were independently predictive of prognosis.
Harvard Medical School, Massachusetts General Hospital, Department of Urology, Boston, MA.
Dayron
D
Rodríguez
Harvard Medical School, Massachusetts General Hospital, Department of Urology, Boston, MA.
Glen W
GW
Barrisford
Harvard Medical School, Massachusetts General Hospital, Department of Urology, Boston, MA.
Alejandro
A
Sanchez
Harvard Medical School, Massachusetts General Hospital, Department of Urology, Boston, MA.
Mark A
MA
Preston
Harvard Medical School, Massachusetts General Hospital, Department of Urology, Boston, MA.
Evgeniy I
EI
Kreydin
Harvard Medical School, Massachusetts General Hospital, Department of Urology, Boston, MA. Electronic address: olumi.aria@mgh.harvard.edu.
Aria F
AF
Olumi
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002675:Child, Preschool; D051642:Histiocytoma / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D006801:Humans; D015994:Incidence; D007223:Infant; D007231:Infant, Newborn; D053208:Kaplan-Meier Estimate; D007890:Leiomyosarcoma / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D008080:Liposarcoma / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D017063:Outcome Assessment, Health Care / Q000379:methods / Q000706:statistics & numerical data; D011379:Prognosis; D012208:Rhabdomyosarcoma / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D012307:Risk Factors; D018426:SEER Program / Q000706:statistics & numerical data; D013085:Spermatic Cord / Q000473:pathology*; D014481:United States / Q000453:epidemiology; D055815:Young Adult
Inguinoscrotal; Outcomes; Paratesticular; Prognostic factors; Sarcoma; Spermatic cord tumor; Survival; Urologic neoplasms